Research Topics
| Martin WehlingSummaryAffiliation: University of Heidelberg Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Translational medicine: science or wishful thinking?Martin Wehling
Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany
J Transl Med 6:31. 2008..It is therefore claimed that a new science needs to be developed called 'translational science in medicine'...- Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100Martin Feuring
Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany
Semin Thromb Hemost 31:411-5. 2005..The aim of this article is to summarize the data obtained from the studies focusing on the monitoring of ASA therapy by the PFA-100... - Translational medicine: can it really facilitate the transition of research "from bench to bedside"?Martin Wehling
Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167, Mannheim, Germany
Eur J Clin Pharmacol 62:91-5. 2006..How can translational medicine improve this apparent mismatch between effort and tangible result for daily medical practice? What is missing, and where do we stand?.. - Nongenomic actions of estrogens: exciting opportunities for pharmacologyMartin Wehling
Department of Clinical Pharmacology Mannheim, University of Heidelberg, Germany
Maturitas 54:321-6. 2006..The further development of such selectively acting drugs holds much promise for better therapies with fewer side effects, e.g. for vascular malfunction, but also for estrogen-dependent cancer... - Non-genomic steroid hormone effects: membrane or intracellular receptors?Martin Wehling
Institute of Clinical Pharmacology Mannheim, University of Heidelberg, Germany
J Steroid Biochem Mol Biol 102:180-3. 2006..Differential pharmacological exploitation of different steroid receptors seems to become a tangible option... - Effects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytesMartin Wehling
Institute of Clinical Pharmacology, Faculty for Clinical Medicine at Mannheim, University of Heidelberg, 68167 Mannheim, Germany AstraZeneca R and D, Molndal, Sweden
Heart Fail Rev 10:39-46. 2005..g. vasoconstriction) by rapid effects on intracellular electrolytes such as free intracellular calcium... - Modulation of angiotensin II-mediated signalling by heparan sulphate glycosaminoglycansHannes Köppel
V Medizinische Klinik, Klinikum Mannheim, University of Heidelberg, Mannheim, Germany
Nephrol Dial Transplant 18:2240-7. 2003..We have now studied the influence of heparin on the Ang II-induced intracellular Ca(2+) release and activation of nuclear factor kappa B (NF-kappaB)... - [Pharmacology of beta blockers and their significance for therapy of hypertension]Martin Wehling
Institut fur Klinische Pharmakologie, Fakultät für Klinische Medizin Mannheim der Ruprecht Karls Universität Heidelberg
Herz 27:16-25. 2002..Hypertension, atrial fibrillation and heart failure are often associated diseases as hypertension is a risk factor for both other diseases... - Meta-analysis of flecainide safety in patients with supraventricular arrhythmiasMartin Wehling
Institute of Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany
Arzneimittelforschung 52:507-14. 2002..Scrutiny should be exercised to diagnose all patients with structural left ventricular damage... - To be or not to be (a receptor)Martin Wehling
Department of Clinical Pharmacology, Medical School Mannheim, University of Heidelberg, D 68167 Mannheim, Germany
Steroids 72:107-10. 2007..However, there is a puzzling variety of candidate receptors described in the literature... - Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIaJob Harenberg
Clinical Pharmacology Mannheim, Vascular Pharmacotherapy, Faculty of Medicine, University of Heidelberg, Mannheim, Germany
Semin Thromb Hemost 34:39-57. 2008.... - Prevention of cold-preservation injury of cultured endothelial cells by catecholamines and related compoundsBenito Yard
V Medizinische Universitätsklinik, Clinical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Am J Transplant 4:22-30. 2004..In conclusion we have demonstrated that catecholamines protect cells against preservation injury either by scavenging of ROS or by inhibition of ROS production... - Assessing the translatability of drug projects: what needs to be scored to predict success?Martin Wehling
Department of Clinical Pharmacology Mannheim, University Medicine Mannheim, University of Heidelberg, Maybachstrasse 14, 68169 Mannheim, Germany
Nat Rev Drug Discov 8:541-6. 2009.... - [Comparison beta-blockers and their relevance to pharmacologic therapy of cardiovascular diseases]Martin Wehling
Institut fur Klinische Pharmakologie, Klinikum Mannheim GmbH, Universitatsklinikum, Fakultät für Klinische Medizin Mannheim, Ruprecht Karls Universitat Heidelberg, Mannheim
Arzneimittelforschung 52:73-80. 2002..Other pharmacological distinctions relate to the selectivity in the beta-adrenergic system, activity in the alpha-adrenergic system and differences in metabolism and elimination... - Multimorbidity and polypharmacy: which betablocker to use in relation to the pharmacokinetic profile and interaction potentialMartin Wehling
Clinical Pharmacology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
Arzneimittelforschung 60:57-63. 2010..The prototype for this type of betablocker is bisoprolol (CAS 66722-44-9)... - Involvement of let-7/miR-98 microRNAs in the regulation of progesterone receptor membrane component 1 expression in ovarian cancer cellsAlexandra Wendler
University of Heidelberg, Clinical Pharmacology Mannheim, Mannheim, Germany
Oncol Rep 25:273-9. 2011.... - Classic versus non-classic receptors for nongenomic mineralocorticoid responses: emerging evidenceRalf M Losel
Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany
Front Neuroendocrinol 29:258-67. 2008..To know the nature of receptors involved may be the key to beneficial medical translation of specific and targeted steroid responses... - Enhancement of beta-adrenergic cAMP-signaling by the mineralocorticoid receptorMichael Christ
Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1, D 68135 Mannheim, Germany
Mol Cell Endocrinol 231:23-31. 2005..In conclusion, our findings suggest a novel interplay between cAMP and MR signaling pathways... - Aldosterone rapidly activates Src kinase in M-1 cells involving the mineralocorticoid receptor and HSP84Sabine Braun
Department of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
FEBS Lett 570:69-72. 2004..Aldosterone led to increased association of Src with HSP84. Furthermore, rapamycin blocked aldosterone-induced Src activation. We conclude that Src activation by aldosterone is mediated through the mineralocorticoid receptor and HSP84... - Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosteroneKarin Rossol-Haseroth
Department of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, 68167 Mannheim, Germany
Biochem Biophys Res Commun 318:281-8. 2004..None of the compounds could block the response to aldosterone. Altogether, the data suggest that rapid aldosterone effects in M-1 cells are initiated by a receptor different from the classical mineralocorticoid receptor... - Acute effects of aldosterone on intracardiac monophasic action potentialsHanns-Christian Tillmann
Faculty of Clinical Medicine Mannheim, Institute of Clinical Pharmacology, Heidelberg University, Theodor-Kutzer-Ufer, 68135, Mannheim, Germany
Int J Cardiol 84:33-9; discussion 39-40. 2002..Therefore, this effect is likely to be mediated nongenomically. It may be hypothesized that aldosterone exerts its unfavorable effects partly via altering myocardial repolarization... - Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjectsMartin Feuring
Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany
J Clin Pharmacol 43:912-7. 2003..91 (0.80, 1.04) and 1.00 (0.91, 1.09) on Days 7 and 11, respectively. Thus, aprepitant, when dosed as a 5-day regimen, did not interact with a known substrate of the P-glycoprotein transporter... - Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?Martin Wehling
Department of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, Heidelberg University, Mannheim, Germany
Clin Ther 26:A21-7. 2004..It is not metabolized by and does not interfere with the cytochrome P-450 enzyme system. These properties meet modern requirements for the treatment of hypertension... - Hypothermic injury: the mitochondrial calcium, ATP and ROS love-hate triangle out of balancePaul Thomas Brinkkoetter
Vth Medical Department, University Hospital of Mannheim, University of Heidelberg, Mannheim, Germany
Cell Physiol Biochem 22:195-204. 2008..Here, we identified cellular processes which govern hypothermia-mediated cell death in endothelial cells and how they are influenced by dopamine... - Early aldosterone up-regulated genes: new pathways for renal disease?Markus Kellner
Institute of Clinical Pharmacology, Faculty of Clinical Medicine at Mannheim, University of Heidelberg, Germany
Kidney Int 64:1199-207. 2003..Further studies should be able to identify other genes regulated in a similar manner that could explain the inefficacy of spironolactone in some cases of aldosterone-mediated kidney disease... - Nongenomic cardiovascular effects of triiodothyronine in euthyroid male volunteersBernhard M W Schmidt
Institute of Clinical Pharmacology, University Hospital of Mannheim, Faculty for Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany
J Clin Endocrinol Metab 87:1681-6. 2002..After pretreatment with esmolol, the effects on SVR and LF/HF ratio were reversed. Our data show, for the first time, nongenomic cardiovascular effects of T(3) in humans... - Position paper: Rapid responses to steroids: current status and future prospectsAlexandra Wendler
Clinical Pharmacology Mannheim, Faculty of Medicine Mannheim, Ruprecht Karls University of Heidelberg, Mannheim, Germany
Eur J Endocrinol 162:825-30. 2010..Additionally, efforts for the propagation of translational studies, which should finally lead to clinical benefit in the area of rapid steroid action research, should be intensified... - Translational research on rapid steroid actionsAlexandra Wendler
Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany
Steroids 75:619-23. 2010..To improve the translational success of the rapid actions of steroids research, scientists should become familiar with major aspects of translational work and always seek for translational dimensions in their research... - Progesterone receptor membrane component 1--many tasks for a versatile proteinRalf M Losel
Clinical Pharmacology Mannheim, University of Heidelberg, Mannheim, Germany
Steroids 73:929-34. 2008..Here, we summarize a few sometimes neglected pieces of evidence from the literature along with unpublished findings on the properties and functions of PGRMC1... - Aldosterone: refreshing a slow hormone by swift actionBrigitte Boldyreff
Department of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer, D-68167 Mannheim, Germany
News Physiol Sci 19:97-100. 2004..Rapid aldosterone effects, which have also been shown in several in vivo studies in humans (e.g., increase in peripheral vascular resistance and blood pressure), are of potential clinical importance... - Novel approaches in the treatment of allergic rhinitisArmin Schultz
Institute of Clinical Pharmacology, Head and Neck Surgery, Faculty of Clinical Medicine Mannheim, Heidelberg University, Mannheim, Germany
Curr Opin Allergy Clin Immunol 3:21-7. 2003..SUMMARY: Promising results, both with established and novel treatment options, are communicated, but further studies are still necessary to confirm these data... - Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatinMichael Christ
Institute of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Heidelberg, Germany
Diabetes 51:2648-52. 2002..Beneficial effects of statins in diabetic patients may be explained in part by attenuation of vascular O(2)(-) formation independent of lipid lowering... - Non-genomic actions of aldosterone: mechanisms and consequences in kidney cellsBrigitte Boldyreff
Department of Clinical Pharmacology, Faculty of Clinical Medicine Mannheim, Heidelberg University, Mannheim, Germany
Nephrol Dial Transplant 18:1693-5. 2003 - Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expressionJohann Bauersachs
Medizinische Klinik der Julius Maximilians Universität, Wurzburg
J Am Coll Cardiol 39:351-8. 2002..We sought to investigate the effects of adding spironolactone (SP) to angiotensin-converting enzyme (ACE) inhibition on endothelium-dependent vasodilation in rats with chronic heart failure (CHF)... - Hormone replacement in postmenopausal women: impact of progestogens on autonomic tone and blood pressure regulationMichael Christ
Department of Internal Medicine Cardiology, University of Marburg, Germany
Menopause 9:127-36. 2002..While hormone replacement therapy (HRT) with estrogens beneficially modulates autonomic tone and blood pressure (BP) regulation in postmenopausal women, the impact of concomitant treatment with progestogens remains unclear... - Proteins interact with the cytosolic mineralocorticoid receptor depending on the ligandMiriam Weber
Klinische Pharmakologie Mannheim, Klinikum Mannheim, Theodor Kutzer Ufer, 68167 Mannheim, Germany
Am J Physiol Heart Circ Physiol 295:H361-5. 2008.... - Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and humanLing Zhang
Vincent Center for Reproductive Biology, Harvard Medical School, Boston, MA 02114, USA
Mol Cell Endocrinol 287:81-9. 2008..These studies provide a platform from which to build a clearer understanding of P(4) actions in the female reproductive tract and placental tissues that are mediated by non-classical mechanisms... - Nongenomic steroid action: controversies, questions, and answersRalf M Losel
, Klinikum Mannheim, Theodor-Kutzer-Ufer, D-68167 Mannheim, Germany
Physiol Rev 83:965-1016. 2003..In addition, clinical implications for a wide array of nongenomic steroid actions are outlined... - Rapid aldosterone actions: from the membrane to signaling cascades to gene transcription and physiological effectsBrigitte Boldyreff
Department of Clinical Pharmacology, Faculty of Clinical Medicine-Mannheim, Heidelberg University, Theodor-Kutzer Ufer 1-3, D-68167 Mannheim, Germany
J Steroid Biochem Mol Biol 85:375-81. 2003..In this work, we discuss the nature of the putative membrane receptor for aldosterone and summarize observed rapid aldosterone effects in different in vitro and in vivo systems... - Rapid effects of aldosterone: relevant in cardiac ischemia?Martin Wehling
Hypertension 46:27-8. 2005 - Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viabilityJohn J Peluso
Department of Cell Biology, University of Conneticut Health Center, Farmington, Connecticut 06030, USA
Biol Reprod 73:261-70. 2005..The exact mechanism of PAIRBP1's action remains to be elucidated, but it may involve an interaction with PGRMC1... - Clinical research in Germany--quo vadis? New activities of the German Diabetes Association and the German Society of EndocrinologyMartin Wehling
Exp Clin Endocrinol Diabetes 111:237-8. 2003 - The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activityNancy G B Agrawal
Merck Research Laboratories, West Point, PA 19486, USA
J Clin Pharmacol 44:1125-31. 2004..Etoricoxib had no effect on hepatic CYP3A activity, as assessed by the erythromycin breath test... - Fighting against the "Hypertriglyceridaemic Waist": a new international institute for the metabolic syndromeHelmut Schatz
Exp Clin Endocrinol Diabetes 111:119-20. 2003